Overview

Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to evaluate the safety, tolerability, and efficacy of divalproex extended release compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Divalproex extended release is approved by the United States Food and Drug Administration (FDA) for the treatment of epilepsy and for prevention of migraine headaches.

Phase:

Phase 3

Details

Lead Sponsor:

Lindner Center of HOPE

Collaborators:

Abbott
University of Cincinnati

Treatments:

Valproic Acid